Skip to content
Clinical Trials – home

Centre Hospitalier Universitaire De La Reunion

Verified siteinfo

France Allee Des Topazes, Cs 11021, 97400 St Denis, France

  • 29 trials recruiting
  • Dermatitis atopic · Systemic lupus erythematosus · Retinoblastoma
  • Adults and children

About Specializations

Centre Hospitalier Universitaire De La Reunion in St Denis, France specialises in clinical trials of conditions such as Dermatitis atopic, Systemic lupus erythematosus, Retinoblastoma, Acute lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Systemic Lupus Erythematosus

The medical center is at the forefront of research in systemic lupus erythematosus, focusing on innovative therapies to reduce disease activity and improve patient outcomes.

  • Effectiveness of cenerimod
  • Long-term Safety and Tolerability

Through rigorous clinical trials, the center is advancing the understanding of lupus management, offering hope for improved quality of life for patients.

Lymphoma

Specializing in peripheral T-cell lymphoma and anaplastic large cell lymphoma, the center is pioneering treatments that aim to enhance progression-free survival and response rates.

  • Autologous Stem Cell Transplantation
  • Nivolumab for Relapsed/Refractory Cases

These studies are crucial in developing personalized treatment strategies that improve patient prognosis and survival rates.

Osteosarcoma

The center is dedicated to improving outcomes for patients with high-risk osteosarcoma through innovative treatment combinations.

  • Mifamurtide with Chemotherapy

By integrating new therapeutic agents, the center aims to enhance event-free survival and reduce relapse rates in affected individuals.

Renal Transplantation

Focusing on pediatric renal transplantation, the center is optimizing anticoagulation therapy to prevent vascular complications.

  • Enoxaparin Dose Adjustment

This research is pivotal in ensuring the long-term success of transplants and improving patient safety.

Syphilis

In the field of early syphilis treatment, the center is evaluating alternative antibiotic regimens to enhance cure rates.

  • Doxycycline vs. BPG

These efforts are aimed at providing more accessible and effective treatment options for patients worldwide.

Breast Cancer

Addressing breast cancer in young women, the center is exploring fertility preservation techniques alongside cancer treatment.

  • Oocyte/Embryo Cryopreservation

This research is vital for maintaining reproductive health and quality of life for young cancer survivors.

Neuroendocrine Cells Hyperplasia of Infancy

The center is investigating treatments for neuroendocrine cells hyperplasia of infancy to improve respiratory outcomes.

  • Methylprednisolone Pulses

These studies are essential for developing effective therapies for this rare pediatric condition.

Retinoblastoma

Focusing on retinoblastoma, the center is advancing conservative treatment strategies to preserve vision and control disease.

  • Intra-arterial Chemotherapy
  • Adjuvant Treatment Post-Enucleation

These efforts are crucial in improving visual outcomes and survival rates in affected children.

Cervical Cancer

In the realm of cervical cancer, the center is evaluating the efficacy of induction chemotherapy to enhance survival rates.

  • Concurrent Chemoradiotherapy

This research is pivotal in refining treatment protocols for advanced cases, aiming to improve patient outcomes.

Prostate Cancer

Specializing in prostate cancer with high-risk features, the center is exploring advanced therapeutic combinations to prevent relapse.

  • Darolutamide and Radiotherapy

These studies are instrumental in developing comprehensive treatment plans that enhance metastasis-free survival.

Vitiligo

The center is at the forefront of research in vitiligo, focusing on novel therapies to promote skin repigmentation.

  • SCENESSE® and NB-UVB Light Therapy

This research is essential in providing effective treatment options for individuals affected by this condition.

Renal Cell Carcinoma

In the field of metastatic renal cell carcinoma, the center is optimizing treatment regimens to improve survival outcomes.

  • Immune Checkpoint Inhibitors
  • VEGFR-Tyrosine Kinase Inhibitors

These efforts are crucial in advancing personalized medicine approaches for this challenging cancer type.

Cardiac Failure

Focusing on cardiac failure post-myocardial infarction, the center is evaluating therapies to improve cardiac function and remodeling.

  • Dapagliflozin Efficacy

This research is vital in enhancing recovery and quality of life for patients with heart failure.

Ependymoma

Specializing in ependymoma, the center is advancing diagnostic and treatment strategies to improve patient outcomes.

  • Centralized MRI Review
  • Post-Operative Chemotherapy

These studies are essential in refining therapeutic approaches for this complex brain tumor.

Lung Cancer

In the realm of non-small cell lung cancer, the center is exploring combination therapies to enhance treatment efficacy.

  • Platinum-Pemetrexed-Atezolizumab

This research is pivotal in developing targeted therapies for patients with specific genetic mutations.

Obesity

The center is investigating treatments for obesity related to genetic variants, focusing on weight management and metabolic health.

  • Setmelanotide Efficacy

This research is crucial in providing effective interventions for individuals with genetic predispositions to obesity.

Subarachnoid Hemorrhage

Specializing in subarachnoid hemorrhage, the center is evaluating therapies to prevent cerebral ischemia and improve recovery.

  • Milrinone Optimization

This research is vital in enhancing outcomes for patients with severe brain hemorrhages.

Respiratory Distress

The center is advancing strategies for respiratory distress management, focusing on optimizing emergency interventions.

  • Tracheal Intubation Optimization

This research is essential in improving patient safety and outcomes during critical care situations.

Acute Promyelocytic Leukemia

Focusing on acute promyelocytic leukemia in children and adolescents, the center is exploring combination therapies to enhance survival rates.

  • ATO and ATRA Combination

This research is crucial in developing effective treatment protocols for young patients with this aggressive leukemia.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Allee Des Topazes, Cs 1102197400 St DenisFrance
Recruiting now
29 trials
Conditions studied
62
Partner status
Verified site

More sites in St DenisFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

60 clinical trials

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Urethral valves

Recruiting

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Intergroupe Francophone Du Myelome

Study on the Effectiveness and Safety of Chikungunya Vaccine (VLA-1553) for People at Risk of Severe Chikungunya in La Réunion

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Trosovavilp alfa
  • Sponsor:Centre Hospitalier Universitaire De La Reunion

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Polycythaemia vera+4

Recruiting

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Study on the Effect of Rocuronium Bromide, Sugammadex, and Suxamethonium Chloride for Adults with Respiratory Distress Requiring Emergency Tracheal Intubation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rocuronium Bromide
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study on Milrinone for Preventing Delayed Brain Ischemia in Patients with Severe Subarachnoid Hemorrhage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Milrinone
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.